This study aimed to validate the Hidradenitis Suppurativa Clinical Response ( HiSCR ) , which is defined as a 50 % reduction in inflammatory lesion count ( sum of abscesses and inflammatory nodules , AN ) , and no increase in abscesses or draining fistulas in HS when compared with baseline as a meaningful clinical endpoint for HS treatment .